Pfizer Corporation

Wyeth

Susan Kay Hoiseth

Kathrin Ute Jansen

Mark Edward Ruppen

Annaliesa Sybil Anderson

Justin Keith Moran

Gary Warren Zlotnick

John Erwin Farley

Lakshmi Khandke

Liesel A Bernfield

Michael Hagen

Yury Vladimirovich Matsuka

Thomas Newell Metcalf, Iii

In one aspect, the invention relates to a non-lipidated and non-pyruvylatedserogroup B polypeptide and methods of use thereof. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide fromserogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup, and methods of use thereof.

composition and methods thereof

The present invention relates to compositions including an isolated non-pyruvylated non-lipidated ORF2086 polypeptide, and methods thereof. In an exemplary embodiment, the compositions described herein are immunogenic. The present invention further relates to compositions that elicit a bactericidal immune response in a mammal against an ORF2086 subfamily B polypeptide from serogroup B, and methods related thereto.

Non-lipidated variants ofORF2086 antigens

In one aspect, the invention relates to a non-lipidated and non-pyruvylatedserogroup B subfamily A A12 polypeptide. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide fromserogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup.

[object Object]

In one aspect, the invention relates to an isolated polypeptide comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 71 in another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide fromserogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup.

In one aspect, the invention relates to an isolated polypeptide comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 71. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide fromserogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup.

Neisseria meningitidis compositions and methods thereof

The present invention provides a method for producing a less-painful immunogenic composition of a hydrophobic protein in a pharmaceutically acceptable carrier suitable for administering to a mammal, comprising the steps of (a) solubilizing said hydrophobic protein with a zwitterionic detergent to make a first composition; (b) altering said first composition, such that the altered composition produces a reduction in pain as measured in the rat footpad model as compared to said first composition.

Growing community of inventors

Tampa, FL, United States of America

Susan Kay Hoiseth